1.8. Analysis.
Comparison 1 Systemic aminocaproic acid versus placebo, Outcome 8 Risk of glaucoma or increases in IOP.
Risk of glaucoma or increases in IOP | ||||
---|---|---|---|---|
Study | Odds Ratio [95% CI] | Total patients (N) | Definition of outcome | Patients with sickle cell/trait |
Transient increase in IOP | ||||
Teboul 1995 | 0.96 [0.18, 5.00] | 94 | Transient IOP greater than 25 mmHg, all patients had normal IOP at discharge (5 days) | None (excluded) |
Persistent increase in IOP | ||||
Kraft 1987 | 1.04 [0.06, 17.69] | 49 | IOP greater than 25 mmHg at follow‐up (6 weeks to 18 months) | None (excluded) |
Kutner 1987 | 0.17 [0.02, 1.81] | 34 | Elevated IOP at time of discharge (6 days) | None (excluded) |